Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clofarabine + busulfan + melphalan
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Clofarabine + busulfan + melphalan (CloB2M) is a myeloablative conditioning regimen composed of three small-molecule chemotherapeutic agents used prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is primarily investigated for adult patients with acute myeloid leukemia (AML) in first complete remission (CR1). The regimen combines clofarabine, a purine nucleoside analogue that inhibits ribonucleotide reductase and DNA polymerase, with two alkylating agents, busulfan and melphalan, which act by cross-linking DNA strands. This combination is designed to provide potent anti-leukemic activity and facilitate successful engraftment in the transplant setting, serving as an alternative to other conditioning backbones such as fludarabine + busulfan-based regimens.
- Other names
- Clofarabine Combined With Busulfan and Melphalan
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on clofarabine + busulfan + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clofarabine + busulfan + melphalan.